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Abstract
 INTERBIO-21  is Phase II of the INTERGROWTH-21Background:
Project, the population-based, research initiative involving nearly 70,000
mothers and babies worldwide coordinated by Oxford University and
performed by a multidisciplinary network of more than 400 healthcare
professionals and scientists from 35 institutions in 21 countries worldwide.
Phase I, conducted 2008-2015, consisted of nine complementary studies
designed to describe optimal human growth and neurodevelopment, based
conceptually on the WHO prescriptive approach. The studies generated a
set of international standards for monitoring growth and neurodevelopment,
which complement the existing WHO Child Growth Standards. Phase II
aims to improve the functional classification of the highly heterogenous
preterm birth and fetal growth restriction syndromes through a better
understanding of how environmental exposures, clinical conditions and
nutrition influence patterns of human growth from conception to childhood,
as well as specific neurodevelopmental domains and associated behaviors
at 2 years of age.
 In the INTERBIO-21  Newborn Case-Control Study, a majorMethods:
component of Phase II, our objective is to investigate the mechanisms
potentially responsible for preterm birth and small for gestational age and
their interactions, using deep phenotyping of clinical, growth and
epidemiological data and associated nutritional, biochemical, omic and
histological profiles. Here we describe the study sites, population
characteristics, study design, methodology and standardization procedures
for the collection of longitudinal clinical data and biological samples
(maternal blood, umbilical cord blood, placental tissue, maternal feces and
infant buccal swabs) for the study that was conducted between 2012 and
2018 in Brazil, Kenya, Pakistan, South Africa, Thailand and the UK.
 Our study provides a unique resource for the plannedDiscussion:
analyses given the range of potentially disadvantageous exposures
(including poor nutrition, pregnancy complications and infections) in
geographically diverse populations worldwide. The study should enhance
current medical knowledge and provide new insights into environmental
influences on human growth and neurodevelopment.
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            Amendments from Version 1
One value in the Methods section relating to perinatal mortality in 
Nairobi has been corrected from “17%” to “1.7%”.
See referee reports
REVISED
Introduction
The International Fetal and Newborn Growth Consortium for 
the 21st Century (INTERGROWTH-21st) Project is a large, 
multicenter, population-based, research initiative, coordinated 
by the University of Oxford and being carried out by a multidis-
ciplinary network of more than 400 healthcare professionals and 
scientists from 35 institutions in 21 countries worldwide. The 
project, involving nearly 70,000 mothers and babies, was 
established to assess human growth, neurodevelopment and 
associated behaviors from early pregnancy to 2 years of age 
under i) healthy conditions and ii) various sub-optimal conditions 
(e.g. maternal infections, malnutrition and pregnancy complica-
tions) and other risk factors for adverse outcomes. 
The Project’s overall mission was guided by a comprehensive 
series of conceptual papers1–4, systematic reviews5–10, epidemio-
logical studies11,12 and evidence-based tools for providing con-
tinuity of clinical care4,13. The insights gained supported the 
project’s guiding principle: namely that the main negative peri-
natal outcomes—fetal death, preterm birth and fetal growth 
restriction (FGR)—are complex, inter-related syndromes that 
require targeted interventions focused on etiological factors.
Phase I of the INTERGROWTH-21st Project, conducted 
between 2008 and 2015, consisted of nine complementary studies 
designed to describe optimal human growth and neurodevelop-
ment, based conceptually on the World Health Organization 
(WHO) prescriptive approach14. Across eight urban areas world-
wide, which were geographically delimited to ensure the study 
was population-based15, we enrolled a large cohort of healthy 
pregnant women before 14+0 weeks’ gestation. The specific aim 
was to monitor their babies prospectively until 2 years of age so 
as to generate international standards for: i) estimating gestational 
age in early and late pregnancy16,17; ii) monitoring symphysis-
fundal height18 and maternal weight gain19; iii) measuring fetal 
size and estimated fetal weight with ultrasound to monitor fetal 
growth20,21; and iv) assessing newborn size for gestational 
age22,23, newborn body composition24 and the postnatal growth 
of preterm infants25. Up to 2 years of age, children included in 
this cohort remained healthy with adequate growth and motor 
development, supporting its appropriateness for the construction 
of international standards26.
In addition, the sequence and timing of attainment of key 
neurodevelopmental milestones and associated behaviours 
among these children at 2 years of age were assessed using a 
tool specifically constructed for the Project27, for implementation 
by non-specialists across international settings28. We have 
demonstrated that developmental patterns were similar across 
these geographically diverse populations when health, nutritional 
and environmental risks were very low29.
Considerable global impact has been achieved in the 3 years 
since the initial results of the INTERGROWTH-21st Project were 
published. For example, the growth standards, which perfectly 
complement the existing WHO Child Growth Standards30, have 
been adopted by WHO31; the Centers for Disease Control and 
Prevention (CDC)32; the Ministries of Health of Brazil, Haiti, 
New Zealand and Sri Lanka; the National Pediatric Society of 
Argentina and the Italian Society of Neonatology. Moreover, the 
INTERGROWTH-21st set of clinical tools, freely available at 
https://intergrowth21.tghn.org, have been downloaded 111,719 
times by users across the world (updated 29 August 2018), and 
more than 10,000 health care professionals have been trained using 
the INTERGROWTH-21st e-learning modules (https://global-
healthtrainingcentre.tghn.org). In addition, the INTERGROWTH-
21st Neurodevelopment Package has been implemented in over 
6500 children in 14 countries, and more than 100 health care 
professionals have been trained in its use. The operation manuals 
and protocols for the Package are freely available at www.inter-nda.
com.
More recently, the Child Health Epidemiology Reference Group 
has selected the INTERGROWTH-21st Newborn Size at Birth 
Standards for gestational age/sex22 as the most reliable tool for 
estimating the prevalence of small for gestational age (SGA) 
in low- to middle-income countries (LMICs) worldwide. They 
reported that 23.3 million infants were born SGA in 2012; 
among these, 11.2 million were term and not low birth weight 
(LBW, ≥2500 g), 10.7 million were term and LBW (<2500 g) and 
1.5 million were preterm33.
The cohort studied in Phase I was selected because the partici-
pants had, both at the population and individual level, the recom-
mended health, nutritional and socio-economic status required 
to construct international standards, i.e. these were generally 
healthy, well-nourished, well-educated mothers living freely in 
environments with minimal constraints on fetal growth, whose 
antenatal care was evidence-based and standardized. Interest-
ingly, the infants in this cohort from LMICs are predicted as 
adults to be approximately 8 cm taller than the mean height of 
their parents, assuming that their health, nutritional and socio- 
economic conditions remain adequate26.
These results, therefore, confirm a pattern and magnitude of 
transgenerational ‘washout’34, that was also seen in the popula-
tions contributing to the WHO Child Growth Standards35. This 
effect on skeletal growth, which can seemingly occur in one 
generation, almost certainly represents a response to environ-
mental changes such as improvements in nutrition and health 
care. However, the mechanisms responsible, which may include 
modifications in gene expression not linked to DNA sequence 
changes, are still to be determined36.
Phase II of the INTERGROWTH-21st Project (The INTERBIO-
21st Study) aims to improve the functional classification of our 
previously evaluated, preterm birth and FGR syndromes11,12 
through a better understanding of how environmental exposures, 
clinical conditions and nutrition influence patterns of human 
growth from conception to childhood. We expect to extend this 
concept to specific neurodevelopmental domains and associated 
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behaviors at 2 years of age at both the individual and population 
level.
The INTERBIO-21st Study’s hypotheses are driven by the 
concept that improvements in the phenotypic characterization 
of these complex syndromes through the integration of clinical 
and laboratory data might facilitate the development of targeted 
screening and preventive strategies, as well as interventions in 
the periconceptual period, pregnancy and infancy. In addition, we 
believe this approach will reveal valuable insights into the role 
of biological factors in high-risk populations. The need is urgent 
given the limited effect of previous efforts, e.g. interventions 
delivered non-specifically to high-risk populations to prevent 
preterm birth and FGR as if these were single clinical entities37.
In the INTERBIO-21st Newborn Case-Control Study, a major 
component of Phase II, our objective is to investigate the mech-
anisms potentially responsible for preterm birth and SGA and 
their interactions, using deep phenotyping of clinical, growth and 
epidemiological data and associated nutritional, biochemical, 
omic and histological profiles. Here we describe the study sites, 
population characteristics, study design, methodology and 
standardization procedures for the collection of longitudinal 
clinical data and biological samples from fetuses, newborns and 
young children who were exposed to a variety of potentially 
disadvantageous intrauterine environments (including poor 
nutrition, pregnancy complications and infections) in geographi-
cally diverse populations worldwide.
Study design principles
The study design principles were included in an original version of 
this protocol, which has been available on the study website mainly 
for our collaborators’ use (https://www.interbio21.org.uk).
Selection of the appropriate control sample in case-control 
studies is one of the most complex issues in epidemiological 
design, and also one in which apparent common sense may 
prove to be wrong, in particular the notion that controls had to be 
“healthy” or “normal” as opposed to only free of the disease 
being studied, i.e. non-cases38. 
There are currently two key concerns regarding selection of 
“controls”. First, controls should represent the population from 
which the cases were selected. This will ensure internal validity 
of the study by avoiding selection bias. It will provide a more 
realistic measure of the magnitude of the association. It is not 
required that controls should be healthy in all respects because 
in the population from which the cases came there will be 
‘unhealthy’ subjects with clinical or subclinical problems or 
pathologies.
Second, control selection should be driven by the epidemiologi-
cal measure of effect that one wishes to estimate. In etiological 
research, the most appropriate measure of effect is the incidence 
density ratio (IDR), or rate ratio, which is equal to the ratio 
between the incidence rates in the exposed and unexposed 
groups. Nevertheless, it is not always possible to estimate the 
IDR directly in case-control designs if the study population is not 
followed up over time.
The two most common designs differ according to the type of 
controls selected. These are the case-non-case design and the 
case-base design. In the former, non-case controls include 
newborns ≥38+0 weeks’ gestation, regardless of whether or not 
they are SGA. As there are many more potential controls than 
cases, controls were sampled to improve the efficiency of the 
study, and to avoid carrying out expensive tests on all non- 
cases. The case-non-case design is easy to explain and provides 
an estimate of the odds ratios associated with specific expo-
sures, which is a good estimate of the IDR when rates of delivery 
<38+0 weeks’ gestation are relatively low, but will overestimate 
the IDR if the delivery rate <38+0 weeks is high. Logistic regres-
sion is the method for analyzing case-non-case designs when 
prevalence is, say, less than 10%, and Poisson regression with 
robust variance when prevalence is higher39.
In the case-base design, controls are sampled from all pregnant 
women, including those who delivered <38+0 weeks’ gestation. 
Such women are, therefore, included as both cases (all women 
delivering at <38+0 weeks’ gestation) and controls (rather a 
sample of these women, using the same sampling fraction as for 
women delivering ≥38+0 weeks). The case-base design estimates 
the prevalence ratio—it is important to remember that preva-
lence is obtained by dividing subjects with a given characteristic 
(for example, birth at <38+0 weeks’ gestation) by the whole pop-
ulation, which includes all births. This justifies the inclusion 
of some women with births at <38+0 weeks’ gestation in the con-
trol group as well. Prevalence ratios obtained from a case-base 
design tend to overestimate the IDR for births at <38+0 weeks’ 
gestation, particularly when the rate of delivery at <38+0 weeks’ 
gestation is high. By collecting data on the four subgroups of 
births (A, B, C and D, see Table 1), it is possible to use weight-
ing to reproduce a case-base analysis. Analyses of case-base 
designs may be carried out using Poisson regression with robust 
variance.
For SGA, the same principles discussed above apply with a few 
modifications. For both case-non-case and case-base designs, 
cases include SGA newborns, defined as birth weight for 
gestational age/sex of the INTERGROWTH-21st Newborn Size 
Standards22. In the case-non-case design, controls would be a 
sample of all newborns who do not present SGA at birth. The 
measure of effect would be the odds ratio, which overestimates 
the IDR and the prevalence ratio when SGA prevalence exceeds 
10%. In the case-base design, SGA at birth is a point preva-
lence measure, more specifically the proportion of all babies 
born with low weight for their gestational age/sex. For example, 
12% of all newborns in a population may present SGA (note that 
the denominator of the prevalence measure includes births with 
and without SGA). The case-base design directly estimates the 
prevalence ratio, because the control group includes a sample of 
all births, regardless of their gestational age at delivery or SGA 
status. It may be argued that for SGA the prevalence ratio is a 
better measure than the IDR, in particular given how hard it is 
to define the precise incidence and timing of SGA onset.
By collecting data on the four subgroups of births (A, B, C 
and D; see Table 1), it is possible to carry out both case-non-
case and case-base analyses in the INTERBIO-21st Newborn 
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Case-Control Study. Initially, we propose that controls should 
be selected from non-cases and that the primary analyses should 
entail case-non-case comparisons. We also plan to carry out 
analyses using a case-base approach, by using statistical weight-
ing to correct for the over-sampling of infants born <38+0 weeks’ 
gestation and those that are SGA, thereby reproducing the whole 
population of births. Further details are provided below.
Methods
Study sites
The INTERBIO-21st Study was conducted between February 
2012 and June 2018 at seven sites: Pelotas (Brazil), Kilifi (Kenya), 
Nairobi (Kenya), Karachi (Pakistan), Soweto (South Africa), 
Mae Sot (Thailand) and Oxford (UK), of which two (Kilifi and 
Mae Sot) were rural and the others urban. The sites in 
Pelotas, Nairobi and Oxford also participated in Phase I of the 
INTERGROWTH-21st Project40–42.
Pelotas (Brazil): The middle-income city of Pelotas, in the 
southernmost region of the country where the richer Brazilian 
states are located, was also the Latin American site for Phase I40. 
Pelotas is the third most populous city in the state of Rio 
Grande do Sul, with 350,000 inhabitants (92% living in urban 
areas) and 4,000 births per year. More than 99% of these births take 
place in the city’s four maternity hospitals. In 2007, Pelotas had a 
per capita gross domestic product (GDP) of R$8248 (US$4933). 
A total of 47% of women in Pelotas receive >9 years of formal 
education, with 21% receiving more than 12 years. Data from the 
Pelotas 2004 birth cohort study indicate that the LBW and FGR 
rates are 10% and 12%, respectively, and that the mean birth 
weight of new-borns is 3150 g43. The city has an Epidemiology 
Research Centre based at the Federal University of Pelotas, 
which has been conducting epidemiological research on mater-
nal and child health nutrition for more than 30 years and is also 
a WHO Collaborating Centre in the field of nutrition. The same 
research team also participated in the WHO Multicentre 
Growth Reference Study (MGRS), which generated the WHO 
Child Growth Standards44. 
Kilifi (Kenya): Kilifi County Hospital (KCH) is located in a 
rural, malaria endemic, coastal area, 55 km north of Mombasa, 
which is the second poorest county in Kenya. The hospital, has a 
catchment area of approximately 280,000 people with 3,000 
births per year. The antenatal HIV prevalence is 7.9%45. KCH 
hosts the Kenyan Medical Research Institute (KEMRI)/Wellcome 
Trust Research Programme, a partnership with the University of 
Oxford that, since 1989, has pioneered work on laboratory-
based, epidemiological and clinical research. In the late 1990s, 
an antenatal ultrasound service was established facilitating 
pregnancy-related research. The research program has a compu-
terized, Health and Demographic Surveillance System (KHDSS) 
that catalogues a sub-population of people living in KCH’s 
predominant catchment area46. Each individual is given a 
personal identification number and births, deaths, in- and out-
migration are recorded at 4-monthly household visits. The 
KHDSS provides a means to encourage attendance at antenatal 
clinics, particularly for booking early in pregnancy. 
Nairobi (Kenya): The relatively wealthy Parklands suburb of 
Nairobi, Kenya, was the sub-Saharan site for Phase I41. Almost 
all births (>4,000) in this geographically delimited urban area, 
which mostly houses affluent Kenyan families, take place in 
three hospitals, the largest of which, The Aga Khan University 
Hospital (AKUH), participated in the study. AKUH is a private, 
not-for-profit, tertiary care institution, which is accessed pre-
dominantly by the middle and high socio-economic sectors. 
These women are able to access the hospital services either 
through medical insurance cover or direct payment; thus, the 
pregnant population served is at relatively low risk of FGR. In 
2008, the mean birth weight was 3101 g; the low birth weight 
and perinatal mortality rates were 11% and 1.7%, respectively. 
Nairobi is a non-endemic malaria area but HIV remains a signifi-
cant problem in the city with a prevalence of 10% in the female 
population although much lower at 1% among women attending 
this hospital for antenatal care. Thanks to wide access to drugs 
and other aspects of care, during the period of this study almost 
all women living with HIV or newly diagnosed during antenatal 
screening had commenced antiretroviral therapy.
Karachi (Pakistan): The Aga Khan University Hospital (AKUH) 
is a philanthropic, not-for-profit teaching institution, which 
caters to a range of socio-economic groups through an effec-
tive patient welfare program. The hospital is the most advanced 
private-sector tertiary care institution in Karachi, the largest city 
in Pakistan with an estimated population of about 20 million 
people. The AKUH is also affiliated with four secondary care 
Table 1. Groups included in the INTERBIO-21st Newborn Case-Control Study.
Set Babies born <38+0 
weeks’ gestation
Babies born 
SGA
Description Number to be included 
in case-control study
A Yes No Non-SGA babies born <38+0 weeks’ 
gestation
A (all)
B No Yes SGA babies born ≥38+0 weeks’ 
gestation
B (all)
C Yes Yes SGA babies born <38+0 weeks’ 
gestation
C (all)
D No No Non-SGA babies born ≥38+0 weeks’ 
gestation
Sample = A+B+C
SGA, small for gestational age.
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hospitals (combined total approximately 15,000 births per year) 
from which high-risk cases are referred as needed: three in 
Karachi and one about 100 miles away. The main AKUH has 
5,800 births per year, a third of which are high-risk. The per 
capita income in Karachi is approximately $1,427. At AKUH, the 
first antenatal visit is usually in the first trimester, at which time 
a dating scan is performed47. Nuchal translucency screening is 
offered to high-risk women and a fetal anomaly scan is offered 
between 19–23 weeks’ gestation.
Soweto (South Africa): Chris Hani Baragwanath Academic 
Hospital (CHBAH), which is attached to the University of the 
Witwatersrand, Johannesburg, South Africa, is the only gov-
ernment hospital serving two sub-districts in southwestern 
Johannesburg, which includes the Greater Soweto area, with a 
population of approximately 1.3 million. CHBAH provides district 
hospital referral services for seven community health centers in 
Greater Soweto, in which midwives conduct low-risk births; 
approximately 5% of births are tertiary referrals from other 
districts and provinces. The hospital has approximately 17,000 
births per year, 75% of which are medium-to-high risk; this 
represents 53% of all births in Greater Soweto48. The HIV preva-
lence is 29%49. The population is urbanized, indigenous African, 
and working-class. The average annual income is substantially 
less than the national average, at approximately US$4,000. 
CHBAH is linked to the Soweto First 1000 Days Study (S1000) at 
the MRC/Wits Departmental Pathways for Health Research Unit 
(DPHRU)50.
Mae Sot (Thailand): The Shoklo Malaria Research Unit (SMRU), 
located on the Thailand-Myanmar border, is a field station 
of the Mahidol-Oxford Research Unit (MORU) of Mahidol 
University, Bangkok. SMRU was established in 1986 as a research 
centre for studying the epidemiology, prevention and treatment 
of resistant malaria (including in pregnancy) among the 130,000 
people living in refugee camps along the border. As there is no 
safe and effective drug for preventing Plasmodium falciparum and 
Plasmodium vivax in pregnancy, women are encouraged to 
attend the antenatal clinic at SMRU every 2 weeks from as early 
as possible in the first trimester, and they are systematically 
screened for malaria at each antenatal consultation and treated 
if positive51. In addition, since 2008, local health workers with 
limited education have been trained at SMRU to take fetal growth 
measurements with great accuracy52. Three of its field sites, with 
a total of approximately 2,100 births per year, participated in 
the study. In 2008, in newborns >28 weeks’ gestation, the mean 
birth weight was 2908g; the LBW and perinatal mortality rates 
were 15.6% and 3.4%, respectively.
Of the sites, two (Wang Pha and Mawker Thai) are clinics for 
migrants; the third, the Maela camp, is the largest refugee camp 
along the border. Both populations remain marginalized: the 
educational level is low and most of available income is obtained 
through intermittent work paid below the minimum wage and 
some women in the camp receive a supplement of refugee food 
rations. In 2012–13, HIV prevalence was low in refugees and 
migrants: 0.27% and 0.61%, respectively53.
Oxford (UK): The John Radcliffe Hospital, Oxford was one of 
the two sites in Europe that participated in Phase I42. Oxford-
shire has a population of more than 650,000 people, which 
includes a large proportion of young, middle-class, well-educated, 
professional families. A total of 37% of the Oxfordshire 
population hold a university degree, 16% higher than the national 
average. The hospital covers approximately 75% of more 
than 8,000 pregnancies that occur annually in this county. The 
general pregnant population served is at low risk of FGR. In 
2008, the mean birth weight was 3334 g; the LBW and perinatal 
mortality rates were 6% and 0.5%, respectively. In addition, 
99% of mothers delivering in the unit have completed secondary 
school or university level education. The hospital also houses the 
University of Oxford’s Nuffield Department of Women’s & 
Reproductive Health, which is where the INTERGROWTH-21st 
Project Coordinating Unit is located.
These sites contributed cases and controls to the INTERBIO-
21st Newborn Case-Control Study, selected using the definitions 
described below.
Case-control definitions
The INTERBIO-21st Newborn Case-Control Study consisted 
of two components evaluating pregnancy characteristics, birth 
outcomes, neurodevelopment and biological markers associated 
with the preterm birth and SGA syndromes. 
The first component aimed to compare preterm phenotypic cases 
to term newborn controls.
Preterm cases were singleton, naturally conceived babies, live- 
born at 23+0 to 37+6 weeks’ gestation2,3, whose mothers were 
≥18 years of age and resided in the hospital’s catchment area 
(to avoid recruiting women referred for tertiary care from 
another geographical region), and whose gestational age was 
estimated by ultrasound measurement of either crown-rump 
length <14+0 weeks’ gestation or head circumference <24+0 weeks’ 
gestation54. For the planned analyses, we will stratify the 
cases by gestational age (defined a priori) into those born 
<37+0 weeks, and those born ≥37+0 but <38+0 weeks’ gestation, 
and according to the previously described phenotypes to explore 
interaction effects11. Cases include groups A and C (Table 1).
For the case/non-case analyses, controls for preterm cases 
were singleton, naturally conceived babies, live-born at 38+0 to 
41+6 weeks’ gestation, and appropriately grown for gestational 
age (AGA), i.e. with a birth weight for gestational age/sex ≥10th 
centile of the INTERGROWTH-21st Newborn Size Standards22, 
whose mothers were ≥18 years of age and resided in the 
hospital’s catchment area, and whose gestational age was 
estimated by ultrasound measurement of either crown-rump 
length <14+0 weeks’ gestation or head circumference <24+0 weeks’ 
gestation54. These controls include groups D and B. For group 
B, the sample will be down-weighted to represent their actual 
occurrence in the population.
A cut-off of 37+6 weeks instead of 36+6 weeks’ gestation was 
used to define a preterm case because of the evidence of a small 
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but nevertheless increased risk of respiratory and other adverse 
neonatal outcomes (including mechanical ventilation, sepsis, 
hypoglycemia, NICU admission, and hospitalization for 5 days or 
more) in those ‘term’ babies born between 37+0 and 37+6 weeks’ 
gestation55.
The second component aimed to compare SGA phenotypic cases 
to term newborn controls.
SGA cases were singleton, naturally conceived babies, live-
born at 23+0 to 41+6 weeks’ gestation, with a birth weight for 
gestational age/sex <10th centile of the INTERGROWTH-21st 
Newborn Size Standards22, whose mothers were ≥18 years of 
age and resided in the hospital’s catchment area, and whose 
gestational age was estimated by ultrasound measurement 
of either crown-rump length <14+0 weeks’ gestation or head 
circumference <24+0 weeks’ gestation54. Cases include groups B 
and C (Table 1).
For the case/non-case analyses, controls for SGA cases were 
singleton, naturally conceived babies, live-born at 38+0 to 
41+6 weeks’ gestation, and AGA, i.e. with a birth weight for 
gestational age/sex ≥10th centile of the INTERGROWTH-21st 
Newborn Size Standards22, whose mothers were ≥18 years of 
age and resided in the hospital’s catchment area, and whose 
gestational age was estimated by ultrasound measurement of 
either crown-rump length <14+0 weeks’ gestation or head cir-
cumference <24+0 weeks’ gestation54. These controls include 
groups D and A. For group A, the sample will be down-weighted 
to represent their actual occurrence in the population.
For the second analytical approach—the case-base analyses— 
controls will include newborns from all four groups. For groups 
A, B and C, the samples will be down-weighted to represent 
their actual occurrence in the population.
Cases were recruited consecutively and one newborn control 
was recruited immediately after each preterm case was recruited; 
similarly, another newborn control was recruited immediately 
after each SGA case was recruited. Both sets of newborn controls 
will be pooled to create a control group for use in the com-
parative analyses with both preterm and SGA cases separately 
(as well as those cases born preterm and SGA), resulting in 
two newborn controls per case and a considerable increase in 
statistical power.
At all sites, trained, dedicated research staff screened all 
women presenting for delivery on a daily basis using a tablet 
(iPad, Apple, USA)-based interface with the data management 
system (https://doi.org/10.5281/zenodo.144266856). The 
software (available on request), that was specially written for 
the study, selected the correct proportion of preterm and SGA 
cases and corresponding controls according to birth weight and 
gestational age. Thus, each newborn recruited fell into one of 
the four groups shown in Table 1.
The software selected a higher proportion of newborns with 
earlier gestational ages (for preterm cases) and lower birth 
weights, i.e. <3rd centile (for SGA cases), using the sampling 
fractions shown in Table 2 so as to avoid recruiting excessive 
numbers just below the cut-offs that represent the majority of 
SGA and preterm newborns, i.e. moderate SGA and late preterm 
newborns. Oversampling cases at the lower end of the gestational 
age and birth weight distributions was important to have a large 
enough sample size to study the highest risk sub-groups; it was 
also expected to increase the statistical power of the study by 
producing a higher proportion of exposures and adverse neonatal 
outcomes.
Slight changes in the sampling fractions (see arrows in 
Table 2) were recommended by the study’s epidemiological 
advisors and introduced for preterm cases in November 2012 
and for SGA cases in November 2013 to reach the recruitment 
rates initially planned. These changes were anticipated because 
the actual recruitment rate of cases was difficult to predict. The 
adjustments were facilitated by the tablet software.
Table 2. Sampling fractions for recruitment in the INTERBIO-21st Newborn 
Case-Control Study.
GA, or BW for GA 
centile (C) To be recruited, % Case/Control
GA <36+0 weeks 
(up to and including 
35+6)
100% Preterm case
GA 36+0 to 36+6 weeks 50% → 100%* Preterm case
GA 37+0 to 37+6 weeks 5% → 20%* Preterm case
BW/GA <C3rd → <C5th# 100% SGA case
BW/GA C3rd - C9.9th 
→ C5th – C9.9th# 50% SGA case
GA 38+0 to 41+6 weeks 
and 
BW/GA ≥ C10th 
Will vary according to 
the number of cases 
recruited
Potential controls to be 
sampled immediately after 
each case
GA, gestational age; BW, birth weight. *Change occurred in November 2012. #Change 
occurred in November 2013.
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We aimed to recruit at least 2,000 cases and 2,000 controls in 
total from the study sites. However, we recognised then that 
power calculations are a great challenge in any field-study of this 
magnitude and even more difficult when exploring risk factors 
with relatively unknown degrees of association and prevalence 
in such populations. The key issue is to reach a balance between 
logistical demands, including the need to maintain data quality 
in these populations, and power calculations especially for the 
planned genetic and epigenetic studies. In addition, when the 
study was designed in 2012, it was extremely difficult to 
provide reliable power calculations for epigenetic studies: 
the field was too new and very few relevant studies had been 
conducted. The compromise was to use experience gained 
from genome-wide association studies to facilitate sample size 
estimations. Thus, 1,500 cases and 1,500 controls (ratio 1:1) 
would be required, assuming a methylation proportion of 0.3 and 
0.2 in cases and controls, respectively, to detect an odds ratio of 
1.7 (population attributable fraction of 0.12) with a significance 
threshold alpha of 5.0 × 10-7 and 90% power. These calcula-
tions included a continuity correction allowing for normal 
approximation of the binomial distribution.
Gestational age estimation by ultrasound
The methods used to estimate gestational age, as well as the 
training, standardization and quality control processes are 
described elsewhere57–59. In brief, crown-rump length measure-
ments were taken <14+0 weeks’ gestation in a mid-sagittal view 
of the horizontal fetus in a neutral position, with an angle of 
insonation as close as possible to 90°. The image could not fill 
less than 30% of the monitor screen. The callipers were placed 
on the outer borders of the head and rump, and gestational age 
was estimated using the INTERGROWTH-21st standards for 
pregnancy dating16.
Head measurements were taken <24+0 weeks’ gestation in an 
axial view at the level of the thalami, with an angle of insona-
tion as close as possible to 90° using the same ultrasound 
machine at each site (Philips HD-9, Philips Ultrasound, USA with 
curvilinear abdominal transducers C5-2, C6-3, V7-3). The head 
had to be oval in shape, symmetrical, centrally positioned, filling 
at least 30% of the monitor. The midline echo (representing 
the falx cerebri) had to be broken anteriorly, at one-third of its 
length, by the cavum septum pellucidum. The thalami had to be 
located symmetrically on either side of the midline. The head 
circumference was measured using the ellipse facility on the 
outer border of the skull, and gestational age was estimated 
using the INTERGROWTH-21st standards for late pregnancy 
dating17.
Femur length was measured using a longitudinal view of the 
fetal thigh closest to the probe and with the femur as close as 
possible to the horizontal plane. The angle of insonation of the 
ultrasound beam was approximately 90° with the full length of 
the bone visualised, unobscured by shadowing from adjacent 
bony parts and the femur had to fill at least 30% of the monitor 
screen. The intersection of the callipers was placed on the outer 
borders of the edges of the femoral diaphysis (outer to outer) 
ensuring clear femoral edges; ultrasound artefacts of the femoral 
edges such as the proximal “trochanter” or pointed femoral 
spurs were not included in the measurement (the detailed 
methodology and a graphical display of how the bone structures 
are localised are available at www.intergrowth21.org.uk). 
The ultrasonographers at each site were selected on the basis 
of their technical expertise, motivation, reliability and ability 
to speak the local language(s). Through rigorous training they 
gained theoretical knowledge and familiarity with the study 
protocol, operations manual, data collection and quality control 
measures. Centralized hands-on training and initial standardiza-
tion were also conducted60, and the Oxford-based Ultrasound 
Quality Control regularly carried out site-specific standardiza-
tion to ensure proper use of the ultrasound equipment, calibration 
and adherence to the protocol. Quality control was maintained 
throughout the study by taking a random 10% sample of all 
ultrasound images and assessing their quality using a validated 
scoring system58.
Anthropometric measures
The anthropometric measurement protocols and quality control 
procedures were identical to those used in Phase I61,62. A 
team of anthropometrists was specially recruited, trained and 
standardized for the study; all training materials were based on 
the original WHO MGRS protocols44. 
In brief, newborn anthropometric measures were ideally obtained 
in all neonates within 12 h of delivery (and no later than 24 h), 
using identical equipment at all sites: electronic scale for birth 
weight (Seca, Hamburg, Germany) and a specially designed 
Harpenden infantometer (Chasmors Ltd, London, UK) for 
recumbent length. The equipment was selected for accuracy, 
precision and robustness, as reported in previous studies44, and 
calibrated twice weekly. Head circumference was measured 
using a metallic non-extendable tape (Chasmors Ltd, London, 
UK). All lead anthropometrists were trained centrally and, in turn, 
trained the local anthropometrists to measure newborns accord-
ing to the study protocol. The Anthropometric Standardiza-
tion Unit based in Oxford regularly monitored the performance 
of all the anthropometrists.
The quality control measures required anthropometrists at 
each study site to take and record all measurements independ-
ently and compare their values with the maximum allowable 
differences. They also checked the forms visually after each 
session to ensure appropriate remeasurements were performed 
when necessary62.
Neonatal outcomes
We will use an un-weighted composite outcome including at 
least one of the following conditions: neonatal death until 
hospital discharge of the newborn, stay in NICU for ≥7 days or 
other severe neonatal complications, such as intraventricular 
hemorrhage and necrotizing enterocolitis. We have used such 
a composite outcome (that, when appropriate, also included 
stillbirths) previously63,64; it requires limited standardization 
of clinical diagnoses across hospitals and is well accepted as a 
marker in large, international, population-based studies of 
newborns that are severely ill65,66. We believe this is a good 
proxy for adverse neonatal outcomes across countries.
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Biological sample processing and storage: INTERBIO-21st 
Biorepository
Biological samples were collected from participants to establish 
a biorepository for a series of planned nutritional, biochemical, 
omic and histological studies. The protocols for processing and 
storing the samples are described briefly below. For each sample 
type, kits containing all the necessary supplies, including tubes 
pre-labelled with a unique aliquot identifier, were prepared by 
GAPPS (Global Alliance to Prevent Prematurity and Stillbirth, 
Seattle, USA) and supplied to each participating site.
Prior to sample collection beginning, the lead laboratory tech-
nician from each site was brought to Oxford for a centralized 
training session. Everyone was trained in collecting, process-
ing and storing samples, as well as recording the associated 
data. Further training sessions were conducted on-site for the full 
laboratory teams every 6–12 months by the global laboratory lead 
to ensure adherence to the protocols and to retrain any staff if 
necessary.
Maternal blood: Maternal blood was collected at delivery and 
routinely processed within 12 h of collection. Plasma was 
divided into up to six 1-ml aliquots; the buffy coat was aspirated 
slowly using a circular motion and stored in a pre-labelled tube. 
After gentle inversion to ensure thorough mixing, the whole 
blood in the EDTA tubes was divided into 1.5 ml aliquots. After 
processing, all relevant information on the collection and 
processing of the plasma, buffy coat and whole blood specimens 
was recorded on the specially designed e-forms and the aliquots 
were stored at −80°C.
Umbilical cord blood: Cord blood was collected within 30 mins 
of delivery of the placenta (or whilst the placenta remained 
in utero). After gentle inversion to ensure thorough mixing, 
the whole blood in the EDTA tubes was divided into 1.5 ml 
aliquots before being stored at -80°C. After collection, the 
blood in the trace element tube was inverted to ensure thorough 
mixing and then left for 30 mins before processing to prevent the 
formation of a gel disc. It was then centrifuged for 10 mins 
at 1200g to separate the plasma (top layer) and buffy coat 
(middle white layer), both of which were retained, from the 
bottom layer of red blood cells that was discarded. The plasma 
was stored in up to three 1 ml aliquots in Nalgene polypropylene 
tubes (Fisher Scientific, Leicestershire, UK); the buffy coat was 
aspirated slowly using a circular motion and also stored in a 
Nalgene polypropylene tube. These tubes were selected as they 
allow subsequent trace element analysis of the plasma sample. 
After processing, all relevant information on the collection 
and processing of the whole blood, plasma and buffy coat was 
recorded on e-forms and the aliquots were stored at -80°C.
Placenta: If processing within 1 h of delivery was possible, 
two placental tissue punches (~8 mm diameter x full placenta 
thickness) from the placental disc, avoiding the site of umbili-
cal cord insertion and at least 3 cm from the edge of the pla-
centa, were collected and placed in a tube preloaded with 3 ml 
RNAlater (Sarstedt, Nümbrecht, Germany) for future estimation 
of RNA. A 0.5 cm membrane strip, cut using scissors or a scalpel 
from the rupture site to the edge of the placental disc, was also 
placed in a tube preloaded with 3 ml RNAlater. These samples 
were stored at 4°C for a minimum of 24 h and a maximum of 
4 weeks before freezing at −80°C. In an area of the placenta 
adjacent to the RNAlater sampling points, two tissue punches of 
similar size (1 cm diameter x full placenta thickness) and a small 
sample of membrane (1 cm wide) were frozen in liquid nitrogen 
or dry ice. A second membrane sample (1 cm wide) and sample 
of the placental disc were placed in formalin for future histology. 
These samples were stored at room temperature for 48–72 h 
after which the formalin was removed, the tissue washed with 
70% ethanol and then transferred to a tube containing 4 ml 70% 
ethanol for long-term storage. 
If the samples could not be processed within 1 h, the placenta 
was stored at 2–8°C for later processing. Within 12 h of delivery, 
samples were collected for freezing and histology (but not 
RNA estimation); if sample processing was possible only at >12 
but <24 h of delivery, samples were collected for histology only. 
Two photographs were taken of the placenta showing the whole 
placenta and umbilical cord with the ‘fetal’ and ‘maternal’ sides 
uppermost. A metric ruler was placed at right angles next to 
the tissue to indicate the size of the placenta. The weight of 
the placenta, trimmed of the cord and all its membranes, was 
recorded.
Maternal feces: A sample of maternal feces (approximately 5 g), 
if passed at delivery, was collected and stored at -80°C.
Buccal swabs: DNA was collected from the infants at 1 and 2 
years of age using a buccal swab collection kit (MAWI DNA 
Technologies, CA 94545, USA). Up to four swabs were gently 
rubbed against the inside of the infant’s cheek and placed into a 
single vial of buffer. After collection, the swabs were discarded 
and the cloudy buffer containing the DNA was stored and 
transported at ambient temperature.
Data management system
All clinical data were managed in a system very similar to the 
one used in Phase I of the INTERGROWTH-21st Project67. In 
brief, the data were initially collected on paper forms capturing 
information relating to ultrasound estimation of gestational age, 
pregnancy & delivery, and any fetal/neonatal abnormalities; 
these forms were securely stored. The data were then entered at 
the local level into an on-line data management system, based 
on the one developed specifically for the INTERGROWTH-21st 
Project (MedSciNet, London, UK). This on-line system, which 
resides on a secure MedSciNet server, facilitated quality con-
trol, correction of errors or missing values, and the initiation of 
data analysis soon after completion of data collection. A review 
process within the system, which involved weekly queries to 
each site via Skype if necessary, ensured that all key data were 
complete. Blinded data from the ultrasound machines were 
transferred directly to the database in Oxford. 
All sample-related data were collected on an electronic form 
(e-form) and the data were uploaded onto a separate data 
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management system (Sapphire, Labvantage Solutions Ltd, High 
Wycombe, UK) that was specifically modified for the study. 
This system, which resides on a secure University server, allows 
samples to be tracked from the time of collection through 
processing, storage at the study sites, and transport to the cen-
tral storage facility in Oxford. Each participant was given a 
unique identifier number, which was used to link the clinical and 
sample databases. Individual aliquots of each sample type were 
also given a unique number.
All the electronically stored data were stripped of personal 
identifiers, which are held separately and securely on site. 
The anonymised databases are only accessible to designated 
personnel, including the Bill & Melinda Gates Foundation as 
part of a data sharing agreement. Users from each study site 
can only view their own data at present and a limited number of 
global administrators can see all the data on a secure server.
These systems provided the Data Management Unit in Oxford 
with a detailed daily record of patient enrolment and data entry, 
at both individual and institutional levels, to monitor progress. 
Corresponding actions, such as telephone calls, web conferences 
and site visits took place within a week of detecting a problem at 
a study site to ensure that appropriate corrective measures were 
taken.
Ancillary studies
INTERBIO-21st Newborn Body Composition Study
Body composition was estimated within 96 h of birth at two 
study sites, Mae Sot and Oxford, using air displacement 
plethysmography (ADP) (PEA POD®, COSMED, Rome, Italy), 
which derives the proportion of fat mass (FM) and fat-free 
mass (FFM) by measuring body volume (air displacement) and 
weight. ADP has considerably improved our understanding of 
newborn body composition and the implications of feeding 
regimens especially for preterm and growth restricted newborns.
This non-invasive technique is rapid, reliable, robust to moderate 
levels of infant activity, and acceptable to parents68. Using the 
same PEA POD methodology, we have previously reported 
normative data at term following the prescriptive approach, 
plus differential FM, body fat percentage and FFM patterns for 
babies born preterm (34+0 to 36+6 weeks’ gestation) and with 
impaired fetal growth24.
The PEA POD, which is designed for use in infants up to 
6 months of age or 8 kg in weight, was routinely calibrated and 
used according to the manufacturer’s instructions in a tempera-
ture-controlled room. The newborn baby was evaluated undressed 
in the test chamber for 2 min and, if necessary, duplicates 
of irremovable items (clamps, tubes or tags) were measured 
before the examination.
This ancillary study tests the hypothesis that pregnancy-related 
etiological factors associated with preterm birth and SGA 
produce differential body composition proportions that can be 
evaluated in the neonatal period. It is expected to contribute 
greatly to the improved phenotypic characterization of these 
complex syndromes.
INTERBIO-21st Postnatal follow-up Study
At 1 and 2 years of age, anthropometric measurements (weight, 
length, head circumference, mid-upper arm circumference, triceps 
skinfold thickness and subscapular skinfold thickness) were 
taken, and data on the infant’s general health, diet and motor 
development skills collected.
In addition, neurodevelopment is being assessed at 2 years 
of age using the INTERGROWTH-21st Neurodevelopment 
Package27. This is a multi-dimensional instrument for early 
child development ideally suited for both research and screen-
ing purposes in field studies and large populations. It was 
designed to be implemented by non-specialist assessors at 
individual and small group levels across varied socio-economic 
and multi-cultural settings. In brief, the Package assesses: 
1)     Cognition, expressive and receptive language, fine and 
gross motor skills, behavior, attentional problems and 
social-emotional reactivity with the INTERGROWTH-
21st Neurodevelopment Assessment (INTER-NDA). 
The INTER-NDA consists of 53 directly administered, 
concurrently observed and maternally reported items 
rated by trained and standardized assessors. Data are 
collected via a tablet-based app called the NeuroApp. 
The INTER-NDA has good reliability across interna-
tional settings and has been validated against the Bayley 
Scales28.
2)     Cortical auditory evoked response potentials to a novelty 
oddball paradigm using gel-free, wireless EEG technol-
ogy (Enobio, Neuroelectrics, Barcelona, Spain) cus-
tomized for 2 year olds, and software which eliminates 
the need for specialist training in neurophysiology69. 
The oddball paradigm consists of a series of frequent, 
infrequent and novel auditory stimuli, which are 
presented via wireless earphones to the infant.
3)     Sleep-wake patterns and daily physical activity, using 
a 6-item sleep questionnaire and actigraphy70. The 
actigraph watch (Motionwatch8, CamNtech Ltd, 
Cambridge, UK) is worn on the infant’s wrist for 
6 days (5 nights) continuously. It measures fine move-
ments at 15 s epochs, and light exposure as well. 
The data are used to calculate sleep and circadian 
rhythm parameters, and to quantify daytime physical 
activity. The operation manuals and protocols are freely 
available at www.inter-nda.com.
4)     Visual acuity and contrast sensitivity with the Cardiff 
tests, which consist of three sets of 11 grey cards each 
with a picture at either the top or the bottom of the 
card71. The cards are presented in a sequence and are used 
to obtain clinically relevant measures of the child’s visual 
acuity and contrast sensitivity. Taken together these two 
observations demonstrate the integrity of the child’s visual 
pathway.
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5)     The gross motor domain of the INTER-NDA was 
complemented with the evaluation of the age of achieve-
ment of the matching WHO gross motor development 
milestones “standing alone” and “walking alone”72. 
Information was obtained at both the 1 and 2-year 
follow-up visits in order to evaluate consistency.
These tools were used to assess the eligible 2-year old children 
in Phase I of the INTERGROWTH-21st Project29. Similarities 
across study sites were measured using variance components 
analysis and standardised site differences (SSD). In 14 of the 
16 domains, the percentage of the total variance explained by 
between-site differences ranged from 1.3% (cognitive score) 
to 9.2% (behavior score); 8% or less for the visual and motor 
items, and <9% for WHO milestones. Of the 80 SSDs com-
parisons, only six were > ±0.50 units of the pooled SD for the 
corresponding item. These data demonstrate that the children of 
healthy, adequately nourished, well-educated pregnant women, 
recruited from five diverse geographical and cultural study 
sites, who receive recommended antenatal care, display con-
sistent similarities at 2 years of age across a comprehensive 
set of neurodevelopmental outcomes. The corresponding 
normative values have been produced for the evaluation of the 
INTERBIO-21st populations and we would like to continue 
following these children until at least the age of 5 years.
Ethics
The INTERBIO-21st Study and its ancillary studies were 
approved by the Oxfordshire Research Ethics Committee “C” 
(reference: 08/H0606/139), the research ethics committees of the 
individual participating institutions, as well as the corresponding 
regional health authorities where the project was implemented. 
All mothers provided written informed consent for the use 
of their clinical data and biological samples. Material Transfer 
Agreements were signed and approved by the relevant national 
regulatory authorities.
Discussion
The overall scientific aim of the INTERBIO-21st Study is to 
improve the functional classification of the complex and highly 
heterogenous preterm birth and FGR syndromes, in particu-
lar through a better understanding of the mechanisms that are 
potentially involved. The aim presupposes that prevention and 
clinical care could be refined, at both individual and population 
levels, if the mechanisms were better understood and phenotypes 
better characterized.
The study directly addresses one of the principal impediments 
to progress in this field: namely that clinical and public health 
practice continue to rely upon the use of rudimentary terminol-
ogy to describe high-risk newborns, e.g. LBW and preterm birth. 
These old, non-specific definitions, which are based upon arbi-
trary cut-offs (2500 g and 37+0 weeks’ gestation) with little 
differential etiological basis, have probably contributed to the 
ineffectiveness or unrealistic expectations of interventions that 
have been used generically in the past, rather than specifically for 
some of the phenotypes described here. In other words, inter-
ventions should no longer be recommended without a detailed 
investigation of the prevalence of the etiological factors 
(attributable risks specific for the different phenotypes) at country 
and regional levels.
An excellent example of the inadequacy of such terms relates to 
the treatment of malaria in pregnancy. A recent systematic review 
and meta-analysis of randomized and quasi-randomized trials 
concluded that prophylactic antimalarial drugs in pregnancy 
may no longer protect against LBW in areas of high-level anti-
malarial resistance73. However, only one of the studies included 
reported SGA as an outcome74; hence, it is unclear whether this 
lack of apparent protection is a reduced effect on fetal growth or 
gestational length, or both.
The rationale, therefore, for improving the phenotypic charac-
terization of these complex syndromes in functional terms is 
simple: the practice of trying to correct the consequences of 
a sub-optimal intrauterine environment without an accurate 
assessment of the gestational age at birth and without taking 
the causes into account makes no biological sense. An accurate 
clinical and epidemiology-based diagnosis is essential so as to 
facilitate the appropriate preventive and care regimens, just as it 
is in other medical specialties.
Over the last decades, it has been repeatedly argued that the 
use of terms such as LBW was a practical necessity because 
many countries cannot collect the information required for more 
detailed characterization, i.e. gestational age estimation. We 
believe that this approach has had negative effects on three 
fronts. Firstly, it has not encouraged improvements in data 
collection in many regions despite technological advances made 
in diagnostics, imaging, digital health and communications. 
Secondly, it has perpetuated recommendations of blanket inter-
ventions at population level and lastly, it has limited epidemio-
logical and service evaluation efforts. Such a limited approach 
is increasingly unacceptable for other complex syndromes, 
i.e. cardiovascular disease75 or malignancy76, even in very 
resource-deprived regions of the world. Why then should maternal 
and newborn health be different?
To achieve our proposed paradigm change, we initiated a two-
phase research initiative. In Phase I, we produced a set of fully 
integrated, international standards, based on an accurate estimate 
of gestational age, that describe optimal growth and neurodevel-
opment. We used the same prescriptive approach as the WHO 
MGRS44, by following the babies of a cohort of healthy, educated 
and well-nourished women from early pregnancy to 2 years of 
age15. The standards, which perfectly complement the existing 
WHO Child Growth Standards, should be used to determine the 
extent to which fetal growth and newborn size deviate from the 
optimum, particularly at a population level, so as to highlight 
inequalities in health care and adverse exposures in pregnancy.
In the INTERBIO-21st Newborn Case-Control Study, we set 
out to improve the phenotypic classification of preterm birth 
and SGA11,12,77, using the clinical tools and international stand-
ards developed in Phase I, as well as the results of planned 
nutritional, biochemical, omic and histological studies and other 
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biomarker studies involving healthy and complicated pregnan-
cies, for which the INTERBIO-21st Biorepository described 
above was assembled. 
The strengths of the INTERBIO-21st Newborn Case-Control 
Study are: i) the use of the same training protocols, standardiza-
tion procedures, data collection methods and quality control 
measures that were employed in Phase I57–59,61,62,67; ii) the highly 
standardized training provided at each site to the dedicated 
research staff who collected, processed and stored all the 
biological samples using a protocol that was developed in 
collaboration with the GAPPS team, and researchers at the 
Universities of Oxford78 and Cambridge79; iii) the rigorous design 
of the case-control study, which included the use of a tablet-
based app for recruitment, removing the need for the research 
staff to make any decisions about eligibility, kept them blind to 
the case or control status of each newborn, and ensured that each 
participant adhered strictly to the recruitment criteria; iv) the 
follow-up to the age of 2 years, which includes neurodevel-
opmental assessment, and v) the availability of newborn body 
composition data in two of the study sites. 
Collecting biological samples from phenotypically well- 
characterized cases and controls at the study sites chosen will 
allow us to explore a wide range of etiological factors and 
exposures that contribute to the development of complicated 
pregnancies, which may now seem to present in the same 
way phenotypically (e.g. low gestational age), as well as the 
interactions between those risk factors and outcomes.
The overall INTERBIO-21st strategy is based on the hypothesis 
that there are a number of pathways leading to adverse perina-
tal outcomes that are mediated by multiple molecular, genetic, 
epigenetic and biochemical mechanisms, with interactive effects 
from risk factors such as infections, nutritional status and other 
environmental exposures. The focus on epigenetics arises 
because of increasing evidence that epigenetic patterns, espe-
cially in the placenta, differentially reflect intrauterine exposure 
to various environmental insults80. It is possible that these inter- 
related pathways may have differential functional effects at 
the level of individual fetal organs and physiological systems, 
with consequences for long-term cardiovascular and metabolic 
health, and neurodevelopment. 
In summary, the INTERBIO-21st Newborn Case-Control Study 
should provide a unique resource for the planned nutritional, 
biochemical, omic and histological analyses to enhance cur-
rent medical knowledge and pave the way for new insights into 
environmental influences on human growth and neurodevelop-
ment. As the results appear, they will be widely disseminated via 
traditional routes, e.g. presentations at international meetings and 
papers in peer-reviewed journals, as well as The Global Health 
Network (https://tghn.org) and social media so as to engage the 
public as much as possible.
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Summary
This paper summarizes the proposed protocol for the INTERBIO-21  Newborn Case-Control Study; no
original data are presented. This proposal represents a major component of Phase II of the original
INTERGROWTH-21  project, a worldwide population-based prospective cohort study conducted from
2008-2015 involving nearly 70,000 maternal-infant dyad study subjects and 400 healthcare professionals
from 35 institutions in 21 countries. The goal of the original study was to develop a contemporary set of
international standards to define normal fetal and childhood growth and neurodevelopment up to 2 years
of age, and to compare these standards across different populations throughout the world.
 Phase II—the proposed INTERBIO-21  Newborn Case-Control Study outlined in this paper—is intended
to leverage the clinical dataset and comprehensive biorepository that has been compiled starting during
Phase I and continuing through 2018 at six locations throughout the world (Brazil, Kenya, Pakistan, South
Africa, Thailand, and the UK). The goal of Phase II is to better understand the pathophysiology of
abnormal pregnancies, specifically those complicated by preterm birth and small-for-gestational age
(SGA). Using deep phenotyping of clinical, epidemiologic, and anthropomorphic data from individual
maternal-infant dyads and integrating this dataset with linked nutritional, biochemical, multi-omic, and
histological information, the investigators aim to better define these heterogeneous syndromes based on
a functional (mechanistic) classification. It is likely that such a classification will improve our
understanding of how environmental exposures, clinical conditions, and nutrition influence patterns of
human growth and neurodevelopment from conception through 2 years of age.
 
General comments:
The INTERBIO-21  Newborn Case-Control Study addresses an important clinical conundrum—namely,
defining the underlying mechanism(s) responsible for the clinical syndromes of preterm birth and
SGA—using a unique, research-quality dataset. This paper describes the study population, study design,
and methodology that will be used in the study as well as the techniques employed to collect the
longitudinal clinical data and biological samples (including maternal blood, umbilical cord blood, placental
tissue, maternal feces, and infant buccal swabs). Overall, the study is well conceived and described.
Cases were consecutive, and appropriate controls (2:1 ratio) and adjustments have been included. A
detailed power analysis is included. A highly respected and experienced team of investigators has been
st
st
st
st
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1.  
2.  
3.  
4.  
detailed power analysis is included. A highly respected and experienced team of investigators has been
assembled. Standardization of biological sample collections, storage in 1.5mL aliquots, and processing
for RNA estimation only if collected within 1 hour (page 10/18, column 2, paragraph 2) represents best
practice. Appropriate ethics approval and written patient consent was obtained (page 12/18, column 1,
paragraph 3). A few specific comments are listed below.  
 
Specific comments:
Preterm birth and SGA cases included pregnancies delivered at or above 23-0/7 weeks (e.g., page
8/18, column 1, paragraph 3). Why was 23 weeks chosen as the cutoff rather than say 24 weeks,
which is more traditional in Europe, or 20 weeks which is commonly used in the US? Please clarify.
Similarly, preterm birth is defined in this study as delivery prior to 38 weeks (i.e., up to and
including 37-6/7 weeks). This is in contrast to the accepted international definition, which is
delivery prior to 37 weeks (i.e., up to and including 36-6/7 weeks). The explanation is included in
the text (page 7/18, column 2, last paragraph and page 8/18, column 1, first paragraph) and is
based on the observation that neonatal outcome is not as favorable during the 37  week (37-0/7 to
37-6/7 weeks) as it is after 38 weeks. This explanation does not make sense. The definition of
‘term’ is just that, a definition; a convention. It is not based on outcome. To follow this argument to
its logical conclusion, if it were determined that neonatal outcome is not as favorable during the 38
 week as it is after 39 weeks, then the definition of preterm birth should be changed to delivery
prior to 39 weeks. And if neonatal outcome is not as favorable during the 39  week as it is after 40
weeks, then the definition of preterm birth should be changed to delivery prior to 40 weeks. This is
not reasonable. The decision to effectively change the definition of ‘term birth’ and ‘preterm birth’
is, in the opinion of this reviewer, a flaw in the study design. Not only will it make it more difficult to
extrapolate the findings, but it will create more overlap between the ‘term’ and ‘preterm’ labor
phenotypes (i.e., result in less extreme clinical phenotypes) thereby making it less likely that
important mechanistic differences will be identified.
It is disappointing that no study subjects were included in the post-term period (i.e., delivery after
42 weeks). While it is to late at this time to make any changes, it is the opinion of this reviewer that
inclusion of a separate cohort of post-term pregnancies may have provided additional insights into
the molecular mechanisms responsible for the onset of labor, both at term and preterm. 
There is reference throughout the paper to “nutritional analysis” as an important environmental
variable. Does this refer to metabolomic analysis of serum samples? Where other sources of
nutritional data included, such as asking study subjects to complete a food diary or a nutritional
survey? Will the analysis include detailed data on breast milk vs formula feeding? What about an
analysis of breast milk? This would certainly affect growth and neurodevelopment in the first 2
years of life.
Is the rationale for, and objectives of, the study clearly described?
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Is the study design appropriate for the research question?
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Are sufficient details of the methods provided to allow replication by others?
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Are the datasets clearly presented in a useable and accessible format?
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© 2018 Stringer J. This is an open access peer review report distributed under the terms of the Creative Commons
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Stringer review of Kennedy et al. Deep clinical and biological phenotyping of the preterm birth and small
for gestational age syndromes: The INTERBIO-21 Newborn Case-Control Study protocol.
 
This manuscript provides a detailed description of the study sites, characteristics of target populations,
study design / methodology, and procedures for data and sample collection in the INTERBIO-21
Newborn Case-Control Study. It is difficult to find much to criticize here. The following notes are minor
points that the authors can either take or leave. There is nothing that I found in my review that should
delay the indexing of this excellent manuscript. 
“Deep” is a popular biomedical adjective that some readers may find confusing when applied to
clinical phenotyping. The manuscript might benefit from a sentence or two describing what is
meant by “deep phenotyping” and how it differs from “phenotyping.”
Presumably because the study is ongoing, there are instances of confusing verb tense throughout.
Some things have been done, others are being done, and still others will be done. Perhaps the
copy editors will be able to help with this, but I found it a little distracting as a reader. 
The section on study design principles gets a bit pedantic (viz, “control selection should be driven
by the epidemiological measure of effect that one wishes to estimate”), but ultimately does a good
job explaining the rationale for how cases and controls were selected. If the authors wanted to
shorten the manuscript, some of this could be replaced with a more straight forward description of
what was done with a bit less justification.
There are 2 instances in the “case-control definitions” section where reference is made to HC as
the basis for gestational age determination (“…and whose gestational age was estimated by
ultrasound measurement of either crown-rump length <14+0 weeks’ gestation or head
circumference <24+0 weeks’ gestation.”  I don’t understand why only HC is mentioned here, when
the INTERGROWTH formula uses both HC and FL to estimate GA. Ref 54 is cited, but this is a
paper about interobserver variability.
What are the sample sizes for the ancillary studies (newborn body composition, postnatal
follow-up)? Are these ancillary studies being done for all enrollees or only a subset?
 
Again, a very clearly written paper with very little to quibble over. There is a lot to be learned from this
study once results start coming in. 
Is the rationale for, and objectives of, the study clearly described?
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Is the study design appropriate for the research question?
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